Kala Pharmaceuticals Inc

$2.05 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Kala Pharmaceuticals Inc

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.

Stock Analysis

last close $2.05
1-mo return -34.1%
3-mo return -45.8%
avg daily vol. 1.58M
52-week high 9.97
52-week low 1.8
market cap. $144M
forward pe -
annual div. -
roe -118.2%
ltg forecast -
dividend yield -
annual rev. $11M
inst own. 51.4%
baraka

Subscribe now for daily local and international financial news

Subscribe